Galactosylation variations in marketed therapeutic antibodies

There are currently ~25 recombinant full-length IgGs (rIgGs) in the market that have been approved by regulatory agencies as biotherapeutics to treat various human diseases. Most of these are based on IgG1k framework and are either chimeric, humanized or human antibodies manufactured using either Chinese hamster ovary (CHO) cells or mouse myeloma cells as the expression system. Because CHO and mouse myeloma cells are mammalian cells, rIgGs produced in these cell lines are typically N-glycosylated at the conserved asparagine (Asn) residues in the CH2 domain of the Fc, which is also the case with serum IgGs. The Fc glycans present in these rIgGs are for the most part complex biantennary oligosaccharides with heterogeneity associated with the presence or the absence of several different terminal sugars. The major Fc glycans of rIgGs contain 0 or 1 or 2 (G0, G1 and G2, respectively) terminal galactose residues as non-reducing termini and their relative proportions may vary depending on the cell culture conditions in which they were expressed. Since glycosylation is strongly associated with antibody effector functions and terminal galactosylation may affect some of those functions, a panel of commercially available therapeutic rIgGs expressed in CHO cells and mouse myeloma cells were examined for their galactosylation patterns. The results suggest that the rIgGs expressed in CHO cells are generally less galactosylated compared to the rIgGs expressed in mouse myeloma cells. Accordingly, rIgGs produced in CHO cells tend to contain higher levels of G0 glycans compared with rIgGs produced in mouse myeloma cell lines. Despite the apparent wide variability in galactose content, adverse events or safety issues have not been associated with specific galactosylation patterns of therapeutic antibodies. Nevertheless, galactosylation may have an effect on the mechanisms of action of some therapeutic antibodies (e.g., effector pathways) and hence further studies to assess effects on product efficacy may be warranted for such antibodies. For antibodies that do not require effector functions for biological activity, however, setting a narrow specification range for galactose content may be unnecessary.

[1]  R. Jefferis.  Aglycosylated antibodies and the methods of making and using them: WO2008030564 , 2009, Expert opinion on therapeutic patents.

[2]  E. Higgins.  Carbohydrate analysis throughout the development of a protein therapeutic , 2009, Glycoconjugate Journal.

[3]  D. James,et al.  Control of Recombinant Monoclonal Antibody Effector Functions by Fc N‐Glycan Remodeling in Vitro , 2005, Biotechnology progress.

[4]  Z. Li,et al.  Optimal and consistent protein glycosylation in mammalian cell culture. , 2009, Glycobiology.

[5]  M. H. Ryan,et al.  Tumor-associated and microbial proteases compromise host IgG effector functions by a single cleavage proximal to the hinge , 2009, Proceedings of the National Academy of Sciences.

[6]  Philippe Girard,et al.  Glycosylation profiles of therapeutic antibody pharmaceuticals. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[7]  B. Scallon,et al.  Quantitative in vivo comparisons of the Fc gamma receptor-dependent agonist activities of different fucosylation variants of an immunoglobulin G antibody. , 2007, International immunopharmacology.

[8]  P. V. van Berkel,et al.  Modulation of antibody galactosylation through feeding of uridine, manganese chloride, and galactose , 2011, Biotechnology and bioengineering.

[9]  B. Scallon,et al.  Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. , 2007, Molecular immunology.

[10]  J. Briggs,et al.  Glycoengineering of therapeutic glycoproteins: in vitro galactosylation and sialylation of glycoproteins with terminal N-acetylglucosamine and galactose residues. , 2001, Biochemistry.

[11]  E. Read,et al.  Industry and regulatory experience of the glycosylation of monoclonal antibodies , 2011, Biotechnology and applied biochemistry.

[12]  Roy Jefferis,et al.  Glycosylation as a strategy to improve antibody-based therapeutics , 2009, Nature Reviews Drug Discovery.

[13]  A. Jones,et al.  Analysis of acidic oligosaccharides and glycopeptides by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. , 1996, Analytical chemistry.

[14]  W. Strohl,et al.  Optimization of Fc-mediated effector functions of monoclonal antibodies. , 2009, Current opinion in biotechnology.

[15]  B. Scallon,et al.  Fc Glycans Terminated with N‐Acetylglucosamine Residues Increase Antibody Resistance to Papain , 2007, Biotechnology progress.

[16]  L. Presta,et al.  Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular Toxicity* , 2002, The Journal of Biological Chemistry.

[17]  W. Strohl,et al.  Discovery and development of biopharmaceuticals: current issues. , 2009, Current opinion in biotechnology.

[18]  Kurt Forrer,et al.  Effect of constant and variable domain glycosylation on pharmacokinetics of therapeutic antibodies in mice. , 2008, Biologicals : journal of the International Association of Biological Standardization.

[19]  J. Reichert.  Antibody-based therapeutics to watch in 2011 , 2011, mAbs.

[20]  I Royston,et al.  IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. , 1997, Blood.

[21]  T. Raju,et al.  Glycosylation Variations with Expression Systems and Their Impact on Biological Activity of Therapeutic Immunoglobulins , 2003 .

[22]  Probabilities of success for antibody therapeutics , 2009, mAbs.

[23]  R. Jefferis,et al.  Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action. , 2009, Trends in pharmacological sciences.

[24]  K. Anumula,et al.  Advances in fluorescence derivatization methods for high-performance liquid chromatographic analysis of glycoprotein carbohydrates. , 2006, Analytical biochemistry.

[25]  T. Raju,et al.  Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics. , 2000, Glycobiology.

[26]  B. Scallon,et al.  Glycosylation in the Fc domain of IgG increases resistance to proteolytic cleavage by papain. , 2006, Biochemical and biophysical research communications.

[27]  Martin Schiestl,et al.  Acceptable changes in quality attributes of glycosylated biopharmaceuticals , 2011, Nature Biotechnology.

[28]  T. Raju,et al.  Terminal sugars of Fc glycans influence antibody effector functions of IgGs. , 2008, Current opinion in immunology.

[29]  Seung-Yeol Park,et al.  Enhanced sialylation of recombinant human erythropoietin in Chinese hamster ovary cells by combinatorial engineering of selected genes. , 2011, Glycobiology.